General

This strategic acquisition substantially expands InnoSer’s preclinical neurology portfolio, adding in vivo rodent models for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis as well as key rare ...

Sylics was founded in February 2007, as spin-off company of the VU University in Amsterdam. In the first few years, Sylics performed behavioural screening of new mouse mutants in several ...

The portfolio of mouse models and CRO services of Sylics has grown over the last decade. To accomodate this expansion we have updated our website. This should help our clients ...

The ongoing COVID-19 pandemic and again rising infection numbers is affecting all of us personally and our businesses. In this situation, Sylics is focused to continue and expand our support ...

Tight timelines? Are you in need to have a drug screening study finished before the end of the year to comply with deadlines or your annual budget? At Sylics, we ...

In humans, the absence of the FMR1 protein leads to Fragile X syndrome, mental retardation and neurodevelopmental delays. The Fmr1 knockout mouse model is perceived as highly translational relevant due to the ...

Sylics characterized an accepted model in the field of schizophrenia research based on a microdeletion in the orthologous human 22q11.2 locus. In humans, a microdeletion of the 22q11.2 locus leads ...

The outbreak of COVID-19 affects all of us worldwide in an unprecedented manner. This requires us all to prioritize care and take disruptive measures to stop spread of the virus. ...

An Alzheimer’s Disease mouse model induced by ‘seeding’ of tau pathology may more closely mimic human tau pathology in comparison to transgenic tauopathy mouse models that overexpress human tau with ...

In order to comply with the new GDPR regulation, Sylics has updated it’s privacy statement to give a clear overview of which personal data is used for what reason. You ...